Leo Pharma

LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting

Retrieved on: 
Saturday, March 18, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Conditional sentence, University, Leo Pharma, BV, Aes, COVID-19, American Academy, Atopic dermatitis, Development, Dermatology, MD, Patient, AAD, LEO, American Academy of Dermatology, Cytokine, Upper respiratory tract infection, Safety, Pharmaceutical industry, EASI

LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.
  • Results were shared as one of two LEO Pharma late breaker oral presentations at the 2023 American Academy of Dermatology (AAD) Annual Meeting.1 LEO 138559 is an investigational agent and its efficacy and safety are subject to further larger trials.
  • LEO Pharma and argenx BV jointly developed LEO 138559 under an exclusive option and research agreement.
  • LEO Pharma obtained the license to LEO 138559 in 2022 and now assumes the responsibility to develop and commercialize LEO 138559 for inflammatory skin disorders, such as atopic dermatitis.

LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 2023

Retrieved on: 
Saturday, March 18, 2023
Managed Care, Pharmaceutical, Health, Clinical Trials, Janus, American Academy of Dermatology, American Academy, JAK, IGA, Leo Pharma, Patient, AAD, CHE, DELTA, Week, Safety, LEO, Pharmaceutical industry, Silviculture

The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.

Key Points: 
  • The DELTA 1 trial randomized 487 adults with moderate-to-severe CHE to twice-daily delgocitinib cream 20 mg/g (n=325) or cream vehicle (n=162) for 16 weeks followed by a 36-week extension trial.
  • A significantly greater proportion of delgocitinib-treated patients, compared to cream vehicle, achieved this IGA-CHE improvement (19.7% vs. 9.9%; p=0.006).
  • A significantly greater proportion of delgocitinib-treated patients achieved a ≥75% improvement in Hand Eczema Severity Index (HECSI-75) compared to cream vehicle (49.2% vs. 23.5%; p
  • We are incredibly excited to share the positive results of this trial, which demonstrates the potential that delgocitinib cream has as a first-in-class innovative topical treatment.”

LEO Pharma Presents New Adbry™ (tralokinumab-ldrm) Data in Adolescent Population from ECZTRA 6 and ECZTEND Trials at AAD 2023 Annual Meeting

Retrieved on: 
Friday, March 17, 2023
Pharmaceutical, Health, Clinical Trials, Keratitis, American Academy of Dermatology, University, Paced Auditory Serial Addition Test, Leo Pharma, S. aureus, Week, Dermatitis, Infection, Food, Aes, American Academy, Atopic dermatitis, Skin, Gene expression, Staphylococcus, Staphylococcus aureus, Malignancy, Patient, AAD, Lower respiratory tract infection, LEO, Annual general meeting, European, Adolescence, PYE, University of Rochester Medical Center, Keratoconjunctivitis, Ageing, AD, FDA, Conjunctivitis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gene, Safety, Pharmaceutical industry, Medical imaging, Vaccine, Tralokinumab

The data was presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting.

Key Points: 
  • The data was presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting.
  • S. aureus is consistently found in the skin lesions of patients with AD and contributes to skin irritation and infections.
  • “In addition, the latest analysis of data from adolescents in the ECZTEND study shows the long-term safety and efficacy profile of Adbry.
  • Adtralza is approved for use in adults with moderate-to-severe AD in the U.S., United Arab Emirates, Switzerland, and Japan.

LEO Pharma Adds Internationally Recognized Dermatologist to Global Leadership Team

Retrieved on: 
Tuesday, March 14, 2023
Health, Other Health, Research, Pharmaceutical, Science, Biotechnology, Bispebjerg Hospital, Canadian industrial research and development organizations, University, Development, Dermatology, Atopic dermatitis, Skin, University of Copenhagen Faculty of Health and Medical Sciences, Patient, LEO, EVP, GLT, Research and development, Pharma, Drug development, Leo Pharma, Delgocitinib, Pharmaceutical industry, Management

To lead Research and Early Development, LEO Pharma has appointed Dr. Jacob Pontoppidan Thyssen as new Executive Vice President and Chief Scientific Officer.

Key Points: 
  • To lead Research and Early Development, LEO Pharma has appointed Dr. Jacob Pontoppidan Thyssen as new Executive Vice President and Chief Scientific Officer.
  • Jacob is an internationally recognized dermatologist and key opinion leader who will add his clinical experience and strong understanding of patients’ needs into LEO Pharma's drug development.
  • To support these two critical pillars, LEO Pharma today announced a split of its Research and Development organization into two distinct areas, both represented in the Global Leadership Team (GLT).
  • I am delighted to welcome Jacob to LEO Pharma and the Global Leadership Team and am confident that his experience will help spearhead our innovative portfolio.

LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology

Retrieved on: 
Friday, March 10, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Partnership, FSP, ICLR, Dermatology, PACE, Clinical trial, ICON, Patient, Head, LEO, Leo Pharma, Communication, Laboratory, Pharmaceutical industry, Fine chemical

LEO Pharma , a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.

Key Points: 
  • LEO Pharma , a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.
  • The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges.
  • Building on earlier collaboration successes within psoriasis trials, LEO Pharma expect to further strengthen its transformation journey by entering a strategic partnership with ICON.
  • “ICON is delighted to enter this partnership with LEO Pharma that truly takes advantage of our breadth of capability and expertise.

LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology

Retrieved on: 
Friday, March 10, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Partnership, FSP, Multimedia, ICLR, Dermatology, PACE, Clinical trial, ICON, Patient, Head, LEO, Leo Pharma, Communication, Laboratory, Pharmaceutical industry, Fine chemical

LEO Pharma , a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.

Key Points: 
  • LEO Pharma , a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.
  • The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges.
  • Building on earlier collaboration successes within psoriasis trials, LEO Pharma expects to further strengthen its transformation journey by entering a strategic partnership with ICON.
  • “ICON is delighted to enter this partnership with LEO Pharma that truly takes advantage of our breadth of capability and expertise.

Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

Retrieved on: 
Monday, March 6, 2023
Abbott Laboratories, NYSE, Leo Pharma, Supervisory board, Krystal, GE, Rare, Patient, KRYS, University, BSE, GE HealthCare, Committee, Management, Engineering

PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the appointment of Catherine Mazzacco to its Board of Directors.

Key Points: 
  • PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the appointment of Catherine Mazzacco to its Board of Directors.
  • Prior to this role, Ms. Mazzacco was Senior Vice President, Global Commercial Operations, Life Sciences Division at GE HealthCare.
  • Ms. Mazzacco is a Member of the Supervisory Board and Remuneration & Nomination Committee of Servier, a privately owned global pharmaceutical company.
  • Ms. Mazzacco holds a BSE, Engineering, Option Biotechnology from the University of Compiègne in France.

argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update

Retrieved on: 
Thursday, March 2, 2023
GMG, SC, FDA, Research, Public expenditure, Leo Pharma, Sale, Marketing, Therapy, SIMPLE, Income tax, Webcast, Janssen, BLA, Video game, Cryptocurrency, Pharmaceutical industry, Life insurance, EU

Collaboration revenue for the fourth quarter and year-to-date in 2022 was $0.8 million and $10 million, respectively, compared to $26 million and $497.3 million for the same periods in 2021.

Key Points: 
  • Collaboration revenue for the fourth quarter and year-to-date in 2022 was $0.8 million and $10 million, respectively, compared to $26 million and $497.3 million for the same periods in 2021.
  • Other operating income for the fourth quarter and year-to-date in 2022 was $7.9 million, and $34.5 million, respectively, compared to $7.7 million and $42.1 million for the same periods in 2021.
  • Loss from investment in joint venture for the fourth quarter and year-to-date in 2022 was $0.7 million.
  • The full year 2022 results and fourth quarter business update will be discussed during a conference call and webcast presentation today at 2:30 pm CET/8:30 am ET.

LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 2 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE), Confirming the Positive Results of the Recent DELTA 1 Trial

Retrieved on: 
Friday, February 10, 2023
Health, Science, Pharmaceutical, Research, Clinical Trials, Janus, Leo Pharma, Delgocitinib, DELTA, CHE, Quality of life, Patient, LEO, JAK, Pharmaceutical industry

LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of the DELTA 2 trial.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of the DELTA 2 trial.
  • DELTA 2 is the second of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
  • Further analyses of the data set will be conducted to determine the full potential of delgocitinib cream in the treatment of adults with moderate to severe CHE.
  • Detailed results from DELTA 2 are planned to be submitted for scientific presentation and publication at a later date.

Cantargia announces appointment of Patrik Renblad as Chief Financial Officer

Retrieved on: 
Wednesday, February 1, 2023
CFO, Forsberg, Leo Pharma, Nasdaq Stockholm, Business administration, Lund University, Economics, IL1RAP, Inflammation, AstraZeneca, Cancer, Pharmaceutical industry, Management, Science

LUND, Sweden, Feb. 1, 2023 /PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA), a clinical-stage biotech company focused on antibody-based therapies targeting IL1RAP for cancer and inflammatory diseases, today announced it has appointed Patrik Renblad as its new Chief Financial Officer (CFO).

Key Points: 
  • LUND, Sweden, Feb. 1, 2023 /PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA), a clinical-stage biotech company focused on antibody-based therapies targeting IL1RAP for cancer and inflammatory diseases, today announced it has appointed Patrik Renblad as its new Chief Financial Officer (CFO).
  • "I am delighted to welcome Patrik Renblad as Cantargia's new CFO.
  • "I would also like to thank Bengt Jöndell for his valuable contribution to building Cantargia over the last six years.
  • Mr Renblad has over 25 years of experience in the healthcare industry, including a number of senior financial positions across multiple geographies.